Teva Pharmaceutical Industries Limited (TEVA) Completes Acquisition Of Labrys: Opens Door To A Strong And Novel Migraine Prevention And Treatment Franchise Within Its CNS Portfolio
7/21/2014 11:20:22 AM
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the successful completion of the acquisition of Labrys. The acquisition of Labrys brings to Teva LBR-101, a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), which is currently in Phase IIb clinical trials for prevention of chronic and episodic migraine. Teva’s acquisition of LBR-101 complements the recent acquisition of ZECUITY®, a novel iontophoretic patch that delivers sumatriptan via the skin for the acute treatment of migraine, and positions Teva to compete for leadership in the treatment and prevention of migraine.
Help employers find you! Check out all the jobs and post your resume.
comments powered by